NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Total Debt
Short-term and long-term borrowings combined.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 88.9% from a year ago
Total debt stood at $934K at the end of Q1 FY2026, down 88.9% from a year earlier and up 48.0% from the prior quarter. Over 3 fiscal years it compounded at -60.9% a year.
Context
- Total debt amounted to 7.8% of total assets at the end of Q1 FY2026, down 102.8 pp from a year earlier.
- Total debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -88.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 631K USD
- Year-over-year change
- -90.4%
- 4-year CAGR
- +5.1%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 631K | -90.4% |
| FY2024 | 2024-12-31 | 6.58M | -28.2% |
| FY2023 | 2023-12-31 | 9.16M | -13.0% |
| FY2022 | 2022-12-31 | 10.53M | +1931.9% |
| FY2021 | 2021-12-31 | 518K | — |
Total Debt vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 total debt of $934K is the 6th highest of the 9 companies compared; the peer median is $5.28M.
- Its year-over-year change of -88.9% is the 7th highest of 9, against a peer median of -13.6%.
- Total debt amounts to 7.8% of total assets for NRXP, versus a peer median of 11.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $230.87M | +23.7% | +9.3% | 175.7% | |
| Mar 2026 | $48.03M | -8.8% | -4.1% | 14.7% | |
| Mar 2026 | $27.19M | -18.4% | +40.2% | 124.2% | |
| Mar 2026 | $7.12M | +210.3% | -51.2% | 12.7% | |
| Mar 2026 | $3.44M | -51.7% | -39.9% | 11.1% | |
| Mar 2026 | $934K | -88.9% | -60.9% | 7.8% | |
| Mar 2026 | $692K | +134.6% | -58.7% | 1.1% | |
| Mar 2026 | $100K | -95.1% | -49.2% | 0.5% | |
| Jun 2026 | $0 | -100.0% | -13.7% | 0.0% | |
| Peer median (excluding NRXP) | $5.28M | -13.6% | -26.8% | 11.9% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.